AstraZeneca PLC (LON:AZN)

London flag London · Delayed Price · Currency is GBP · Price in GBX
10,754
+146 (1.38%)
May 2, 2025, 6:17 PM BST
-11.64%
Market Cap 166.76B
Revenue (ttm) 42.56B
Net Income (ttm) 6.02B
Shares Out 1.55B
EPS (ttm) 3.85
PE Ratio 27.96
Forward PE 15.31
Dividend 2.41 (2.24%)
Ex-Dividend Date Feb 20, 2025
Volume 2,160,165
Average Volume 3,108,087
Open 10,656
Previous Close 10,608
Day's Range 10,599 - 10,792
52-Week Range 9,574 - 13,388
Beta 0.18
RSI 51.59
Earnings Date Apr 29, 2025

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]

Sector Healthcare
Founded 1992
Employees 94,300
Stock Exchange London Stock Exchange
Ticker Symbol AZN
Full Company Profile

Financial Performance

In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.

Financial numbers in USD Financial Statements

News

AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma

AstraZeneca's Breztri met primary goals in ... Full story available on Benzinga.com

3 days ago - Benzinga

Alembic Pharma gets USFDA final nod for Ticagrelor 90 mg, tentative approval for 60 mg

Alembic Pharmaceuticals Limited announced on May 2, 2025, that it has received final approval from the US Food and Drug Administration (USFDA) for its Ticagrelor Tablets, 90 mg, and tentative approval...

3 days ago - Business Upturn

AstraZeneca's Breztri meets main goals of late-stage asthma trials

Anglo-Swedish drugmaker AstraZeneca on Friday said its inhaler therapy Breztri Aerosphere met all the main goals of two late-stage trials in patients with uncontrolled asthma.

3 days ago - Reuters

Step up now or lose jobs to US, AstraZeneca boss Pascal Soriot warns European pharma firms

Pascal Soriot (pictured) said innovation in pharma 'has mostly been funded by the US' as he doubled down on plans to grow the business in America.

6 days ago - This is Money

What Does the Market Think About AstraZeneca?

AstraZeneca's (NYSE: AZN) short percent of float has fallen 41.18% since its last report. The company recently reported that it has 6.33 million shares sold short , which is 0.2% of all regular share...

6 days ago - Benzinga

AstraZeneca has built resilient supply chains in U.S., China: CEO

AstraZeneca CEO Pascal Soriot discusses earnings, the potential trade tariff impact on the business and the outlook for the firm's key markets.

6 days ago - CNBC International TV

Pharma firms maastraz

Jimmy Muchechetere, senior equity analyst at Investec, weighs in on the prospect of pharmaceutical tariffs and recent U.S. investment commitments from the sector.

6 days ago - CNBC International TV

AstraZeneca PLC (AZN) Q1 2025 Earnings Conference Call Transcript

AstraZeneca PLC (NASDAQ:AZN) Q1 2025 Earnings Conference Call April 29, 2025 6:45 AM ETCompany ParticipantsAndy Barnett - Head of IRPascal Soriot -...

6 days ago - Seeking Alpha

AstraZeneca CEO talks tariffs, first quarter earnings

AstraZeneca (AZN) reported mixed first quarter earnings results, missing on revenue estimates but beating on earnings per share (EPS). The company also reaffirmed its 2025 outlook and has highlighted ...

6 days ago - Yahoo Finance

AstraZeneca Q1 Earnings Rise, But China Drug Allegations May Lead To $8 Million Penalty

AstraZeneca Plc (NASDAQ: AZN) on Tuesday reported first-quarter 2025 sales of $13.59 billion, up 7% year over year (+10% at constant currency), slightly missing the consensus of $13.71 billion , driv...

6 days ago - Benzinga

AstraZeneca Q1 Earnings Rise, But China Drug Allegations May Lead To $8 Million Penalty

AstraZeneca Plc AZN on Tuesday reported first-quarter 2025 sales of $13.59 billion, up 7% year over year (+10% at constant currency), slightly missing the consensus of $13.71 billion, driven by double...

6 days ago - Benzinga

AstraZeneca Beat Earnings Views, But Sales Come In Light As Cancer Study Flops

AstraZeneca stock was little moved Tuesday on a mixed earnings report and after the drug giant scrapped a failed cancer study.

6 days ago - Investor's Business Daily

AstraZeneca gets EU backing for lymphocytic leukemia treatment

EMA panel backs AstraZeneca's Calquence combo for leukemia. Read more here.

6 days ago - Seeking Alpha

Drugmaker AstraZeneca shifts more production to US amid Trump tariffs

UK and rest of Europe risk losing out to US and China unless they ramp up spending on new medicines, says CEO Pascal Soriot Business live – latest updates AstraZeneca said it was shifting the producti...

6 days ago - The Guardian

AstraZeneca CEO hopes U.S. will represent half of company’s global revenue by 2030—vows to invest and expand in nation despite tariff threat

AstraZeneca's first quarter profit has risen by over 30 percent to $2.92 billion. The pharmaceutical giant said it remains on track to achieve its total target of $80 billion in annual revenue by 2030...

6 days ago - Fortune

AstraZeneca PLC 2025 Q1 - Results - Earnings Call Presentation

The following slide deck was published by AstraZeneca PLC in conjunction with their 2025 Q1 earnings call.

6 days ago - Seeking Alpha

AstraZeneca to keep 2025 forecast if US pharmaceutical tariffs in line with other sectors

The chief executive of AstraZeneca said on Tuesday that the drugmaker will maintain its 2025 sales guidance even if the U.S. levies tariffs on pharma products made in the European Union, provided they...

6 days ago - Reuters

AstraZeneca has built resilient supply chains in the U.S. and China for years, doesn't expect much tariff impact, CEO says

AstraZeneca CEO Pascal Soriot discusses earnings, the potential trade tariff impact on the business and the outlook for the firm's key markets.

6 days ago - CNBC

AstraZeneca Sales, Earnings Rise; Warns of Mounting Legal Challenges in China

The drugmaker posted increased core earnings per share and sales for the first quarter, but also said it could face a fine of up to $8 million in China.

6 days ago - WSJ

European stocks head for mixed open as investors eye tariff impact on earnings

European stocks were set for a mixed open on Tuesday, with results out from HSBC, Lufthansa, Volvo Cars, Adidas, BP, AstraZeneca, Deutsche Bank and more.

6 days ago - CNBC